Data gathered: July 3
AI Stock Analysis - Biomarin Pharmaceutical (BMRN)
Analysis generated October 14, 2024. Powered by Chat GPT.
Biomarin Pharmaceutical Inc. is a prominent biotechnology company that focuses on developing and commercializing innovative biopharmaceuticals for serious and life-threatening rare genetic diseases and conditions. Headquartered in San Rafael, California, Biomarin's portfolio includes a wide array of products that address diverse therapeutic areas such as metabolic disorders and enzyme replacement therapies. Through relentless research and development, the company aims to bring hope to patients and families affected by rare genetic disorders.
Stock Alerts - Biomarin Pharmaceutical (BMRN)
 |
Biomarin Pharmaceutical | June 17 Employee Rating is down by 2.7% over the last month. |
|
Biomarin Pharmaceutical | June 17 Business Outlook among employees is down by 10.5% over the last month. |
|
Biomarin Pharmaceutical | May 21 Insider Alert: Burkhart Erin is selling shares |
|
Biomarin Pharmaceutical | May 13 Business Outlook among employees is down by 4.8% over the last month. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Biomarin Pharmaceutical
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 113 | Sign up | Sign up | Sign up |
| Sentiment | 94 | Sign up | Sign up | Sign up |
| Webpage traffic | 75,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | 9 | Sign up | Sign up | Sign up |
| Patents | 75 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 34 | Sign up | Sign up | Sign up |
| Facebook Followers | 6,142 | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 18 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,182 | Sign up | Sign up | Sign up |
| Twitter Mentions | 81 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 1,940 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 34 | Sign up | Sign up | Sign up |
| Linkedin Employees | 3,112 | Sign up | Sign up | Sign up |
About Biomarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
| Price | $57.17 |
| Target Price | Sign up |
| Volume | 2,950,000 |
| Market Cap | $10.8B |
| Year Range | $54.08 - $72.83 |
| Dividend Yield | 0% |
| PE Ratio | 20.81 |
| Analyst Rating | 85% buy |
| Industry | Biotechnology |
In the news
BioMarin Pharmaceutical Inc.(NasdaqGS: BMRN) dropped from Russell 1000 Value-Defensive IndexJune 30 - Finnhub |
|
 |
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by Robeco Institutional Asset Management B.V.June 30 - ETF Daily News |
BioMarin Pharmaceutical Inc.(NasdaqGS: BMRN) dropped from Russell 1000 Defensive IndexJune 29 - Finnhub |
|
|
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by Asset Management One Co. Ltd.June 29 - ETF Daily News |
|
Wealth Enhancement Advisory Services LLC Boosts Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)June 28 - ETF Daily News |
 |
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-TermJune 26 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 745M | 152M | 594M | 186M | 224M | 1.130 |
| Q4 '24 | 738M | 136M | 602M | 125M | 196M | 0.920 |
| Q3 '24 | 746M | 188M | 557M | 106M | 156M | 0.550 |
| Q2 '24 | 709M | 145M | 564M | 107M | 162M | 0.560 |
| Q1 '24 | 649M | 139M | 509M | 89M | 136M | 0.460 |
Insider Transactions View All
| Burkhart Erin filed to sell 14,173 shares at $59.3. May 20 '25 |
| Hubbard Cristin filed to sell 32,700 shares at $64.9. May 6 '25 |
| Burkhart Erin filed to sell 16,955 shares at $71.5. March 20 '25 |
| Guyer Charles Greg filed to sell 87,655 shares at $71.3. March 7 '25 |
| Burkhart Erin filed to sell 13,105 shares at $68.4. February 25 '25 |
Similar companies
Read more about Biomarin Pharmaceutical (BMRN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Biomarin Pharmaceutical?
The Market Cap of Biomarin Pharmaceutical is $10.8B.
What is Biomarin Pharmaceutical's PE Ratio?
As of today, Biomarin Pharmaceutical's PE (Price to Earnings) ratio is 20.81.
What is the current stock price of Biomarin Pharmaceutical?
Currently, the price of one share of Biomarin Pharmaceutical stock is $57.17.
How can I analyze the BMRN stock price chart for investment decisions?
The BMRN stock price chart above provides a comprehensive visual representation of Biomarin Pharmaceutical's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Biomarin Pharmaceutical shares. Our platform offers an up-to-date BMRN stock price chart, along with technical data analysis and alternative data insights.
Does BMRN offer dividends to its shareholders?
As of our latest update, Biomarin Pharmaceutical (BMRN) does not offer dividends to its shareholders. Investors interested in Biomarin Pharmaceutical should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Biomarin Pharmaceutical?
Some of the similar stocks of Biomarin Pharmaceutical are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.